Analysts See $-0.67 EPS for CRISPR Therapeutics AG (CRSP) on May, 10


It’s down -0.24, from 1.46 in 2017Q3. The investment professionals in our database reported: 11.31 million shares, down from 11.69 million shares in 2017Q3.

RAIFFEISEN BANK INTERNATIONAL AG WIEN OR (OTCMKTS:RAIFF) had an increase of 0.57% in short interest.

Analysts await CRISPR Therapeutics AG (NASDAQ:CRSP) to report earnings on May, 10. The stock increased 2.34% or $1.11 during the last trading session, reaching $48.52.

Shares of CRSP opened at $49.09 on Friday. CRISPR Therapeutics AG (NASDAQ:CRSP) has risen 144.93% since May 3, 2017 and is uptrending. CRSP outperformed the S&P 500 by 133.38%. The stock increased 1.72% or $0.1 during the last trading session, reaching $5.9. About 582,290 shares traded or 356.56% up from the average. (Rating Scale: 1.0 Strong Buy, 2.0 Buy, 3.0 Hold, 4.0 Sell, 5.0 Strong Sell). Its up 0.57% from 52,400 shares previously. CRISPR Therapeutics has a one year low of $13.50 and a one year high of $61.24. Finally, Citigroup upped their price target on shares of CRISPR Therapeutics from $20.00 to $51.00 and gave the company a “neutral” rating in a report on Wednesday, February 28th. AFAM was included in 2 notes of analysts from October 19, 2016. Zacks Investment Research downgraded CRISPR Therapeutics from a hold rating to a sell rating in a research report on Thursday, January 25th. The Nwq Investment Management Company Llc holds 1.20M shares with $22.82M value, up from 953,454 last quarter. It also provides investment banking services, which include equity capital markets; mergers and acquisitions, privatizations, and private placements; asset based finance; and debt capital market and loan syndication services, as well as arranges Schuldscheins issued by national and global borrowers to corporate customers, and institutional and private investors.

Almost Family, Inc., together with its subsidiaries, provides home healthcare services in the United States. The stock has a market cap of $2,236.18, a price-to-earnings ratio of -27.94 and a beta of 3.58. The Company’s Visiting Nurse Services segment offers a range of Medicare-certified home health nursing services to patients in need of recuperative health care, as well as services to patients in lieu of additional care in other settings, including long term acute care hospitals, inpatient rehabilitation hospitals, or skilled nursing facilities. This segment also provides special clinically protocols to medically complex, chronic, and co-morbid patients.

More important recent CRISPR Therapeutics AG (NASDAQ:CRSP) news were published by: which released: “Intellia up 8% premarket after CRISPR/Cas9 patent arguments” on May 01, 2018, also published article titled: “CRISPR pioneer Doudna behind genetic testing startup”, published: “Crispr sees gene therapy milestone in Europe” on April 16, 2018. Therefore 80% are positive. SunTrust Banks reissued a “buy” rating and set a $65.00 target price on shares of CRISPR Therapeutics in a research report on Friday, March 9th. The firm issued a buy rating and a $86.00 price target on the stock. The rating was initiated by Barclays Capital with “Overweight” on Monday, November 14.

– Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with our FREE daily email newsletter.


Leave A Reply